Immunologic Factor – Page 3

Akeso; Summit Therapeutics; ivonescimab; PD-1xVEGF; bispecific antibody; non-small cell lung cancer; progression-free survival; Phase 3 trial; overall survival; FDA approval

Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China

2 weeks ago talkbio0Tagged Akeso, Ankylosing spondylitis, Autoimmune Diseases, China, Clinical Trials, Dermatitis, Atopic, Gumokimab, Manfidokimab, regulatory submission

Akeso; Phase 3 trials; gumokimab; manfidokimab; ankylosing spondylitis; atopic dermatitis; regulatory submission; China; autoimmune diseases; clinical trial results

Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix

3 weeks ago talkbio0Tagged aspects of adverse effects, Dynavax, Effectiveness, Herpes zoster disease, Immunogenicity (package insert), Shingrix, Vaccines, Z-1018

Dynavax; Z-1018; shingles vaccine; Shingrix; vaccine efficacy; side effects; Phase 1/2 trial; immunogenicity

American Academy of Pediatrics Breaks with RFK Jr., CDC on COVID Vaccines for Kids

3 weeks ago talkbio0Tagged Academy of Pediatrics, antiarrhythmic peptide, Centers for Disease Control and Prevention (U.S.), Child, COVID19 (disease), Immunization, Pediatric brand name, Policy, public health guidance, Robert F. Kennedy, Vaccines

American Academy of Pediatrics; AAP; COVID-19 vaccine; children; CDC; Robert F. Kennedy Jr.; pediatric immunizations; public health guidance; vaccine policy

CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts

3 weeks ago talkbio0Tagged cost-cutting, demerger, Seqirus, SMPX gene, strategic restructuring, Vaccines

CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting

Conflicts of Interest Among Federal Vaccine Advisors at Historic Lows Through 2024

3 weeks ago talkbio0Tagged ACIP, Advisory Committees, Centers for Disease Control and Prevention (U.S.), JAMA study, Robert F. Kennedy Jr., Translucent, United States Food and Drug Administration, Vaccines, VRBPAC

conflicts of interest; vaccine advisory committees; ACIP; VRBPAC; CDC; FDA; transparency; Robert F. Kennedy Jr.; JAMA study

Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies

4 weeks ago talkbio0Tagged Adaptive Biotechnologies, Cell Therapy, Collaboration termination, genentech, personalized cancer, T-Cell Receptor, TruTCR

Genentech; Adaptive Biotechnologies; cell therapy; collaboration termination; T-cell receptor; TruTCR platform; personalized cancer therapy; $2 billion deal